"Wise Policy" Needed To Link Comparative Effectiveness with Individualized Medicine
This article was originally published in RPM Report
As comparative effectiveness matures from a political rallying cry and budget strategy to a process that the medical community will have to face as a new force with more financial and public support, the most thoughtful people in medicine are trying to find a way to understand the term and how it fits into other trends. It's not easy, even for them.
You may also be interested in...
FDA’s idea to encourage “voluntary” submission of pharmacogenomic data started slow—but the program has paid significant dividends for the agency. In addition to building knowledge and advancing the use of PKG in drug regulation, it has also won over industry and become a case study to support broader funding of regulatory science.
Francis Collins' intellectual agility and experience working on huge initiatives with a lot of moving parts - the human genome project comes to mind - will serve him well as the National Institutes of Health's director
Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.